Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Structure Therapeutics Inc. Director's Dealing 2025

Jul 3, 2025

31940_dirs_2025-07-03_d2bbf86e-dbff-4fda-bb02-574526cc1278.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Structure Therapeutics Inc. (GPCR)
CIK: 0001888886
Period of Report: 2025-03-01

Reporting Person: Coll Crespo Blas (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-03-01 Ordinary Shares F 1233 $7.9166 Disposed 218355 Direct
2025-07-01 Ordinary Shares A 7992 Acquired 226347 Direct
2025-07-01 Ordinary Shares F 1434 $6.8366 Disposed 224913 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2025-05-21 American Depositary Shares $ A 429 Acquired Ordinary Shares (1287) Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
American Depositary Shares $ Ordinary Shares (3000) 1000 Indirect

Footnotes

F1: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer.

F2: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a restricted share unit award.

F3: On March 15, 2024, the reporting person was granted performance-vesting restricted share units ("PSUs"), each of which represents a contingent right to receive one Ordinary Share of the Issuer, which vest upon satisfaction of certain performance criteria. Certain of the performance criteria was determined to have been met effective July 1, 2025. The shares subject to the PSUs vest as follows: 50% of the shares vested on July 1, 2025 and the remainder will vest on January 1, 2027 subject to the reporting person's Continuous Service (as defined in the Structure Therapeutics Inc. 2023 Equity Incentive Plan) through such vesting date.

F4: Each ADS is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The ADSs have no expiration date.

F5: Voluntary reporting of the acquisition of 429 ADSs by the Reporting Person on May 21, 2025 pursuant to the Issuer's Employee Share Purchase Plan.